Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Satu Pekkala has a total of 280 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prebiotic xylo-oligosaccharides cause modest taxonomic shifts in the gut microbiota but do not increase insulin sensitivity in insulin resistant individuals

    by Anastasiia Driuchina, Jenni Hekkala, Jukka Hintikka, Perttu Permi, Ella Hellsten, Sanna Lensu, Viktor Bielik, Jari Laukkanen, Satu Pekkala

    Background: Overweight increases the risk of Type 2 Diabetes (T2D), and insulin resistance (IR) precedes development of T2D. Besides lifestyle factors, gut microbes and their metabolites contribute to IR. Gut microbiota could be modulated by probiotics and prebiotics to improve IR, but current research results from interventions are controversial. We aimed at exploring the effects of prebiotic xylo-oligosaccharides (XOS) on the structure and metabolites of gut microbiota, IR, body composition and inflammatory response in humans with overweight. Methods: In this within-subjects study design the participants had a 1-month baseline control period without changing their lifestyle and then, they were subjected to 4-months of dietary XOS supplementation. Based on baseline HOMA-IR, we divided study participants into insulin sensitive (< 3, IS, n = 11) and insulin resistant (> 3, IR, n = 38) groups. The gut microbiota were analyzed using 16 S rRNA gene sequencing. Fecal metabolomes were quantified using nuclear magnetic resonance spectroscopy (NMR). Additionally, blood clinical variables, serum cytokines, body composition and diet were studied. Results: We identified clear differences between insulin-resistant (IR) and insulin-sensitive (IS) participants in gut microbiome, body composition, and glucose–insulin profiles, along with modest variations in proinflammatory cytokines. Although four months of XOS supplementation did not alter insulin sensitivity or most other measured outcomes, it slightly reduced the levels of total cholesterol and increased HDL cholesterol in IR participants. However, it should be noted that during control period HDL first decreased in that group. Interestingly, XOS treatment decreased fecal galactose, isobutyrate, and isovalerate levels in IS participants, whereas shifts in microbial abundances (20 different microbial taxa) were observed only in IR participants with no changes in diversity. Isobutyrate, isovalerate and phenylacetate levels were lower in the IR group at baseline compared to IS. Across the study from baseline to post-treatment, body weight and BMI declined in IR individuals. Conclusions: XOS supplementation altered gut microbiota composition in IR participants, while changing fecal metabolome in IS participants. XOS modestly improved lipid parameters, such as HDL cholesterol, but did not improve insulin sensitivity, body composition, or inflammatory markers. More and larger studies are needed to show that prebiotic XOS can consistently improve insulin sensitivity. Trial registration: The study was retrospectively registered at ISRCTN under the number ISRCTN86495943.

  • Open Access

    Effects of a multicomponent exercise regimen on subchondral bone and cartilage in postmenopausal women with knee osteoarthritis: protocol for a randomized controlled trial

    by Ville-Markus Konola, Jari Parkkari, Juhani Multanen, Riku Nikander, Timo Rantalainen, Johanna Vesanto, Satu Pekkala, Merja Kalaja, Johanna K. Ihalainen, Benjamin Waller, et al.

    Background: Knee osteoarthritis (KOA) is considered a whole-joint disease that is amenable to prevention and treatment in the early stages. Exercise is among the core treatment recommendations for KOA and it has been suggested that optimal exercise regimens should improve aerobic capacity and knee extensor strength. Subchondral bone and articular cartilage are functionally paired, and information on the responses of these tissues to exercise may help in the development of efficacious and feasible exercise regimens that can potentially improve bone and cartilage properties. This article describes a clinical trial investigating the effects of a multicomponent exercise regimen on the subchondral bone and articular cartilage of the knee joint in postmenopausal women with mild KOA. Methods: A minimum of 90 postmenopausal women between the ages of 55 and 75 meeting the inclusion criteria will be recruited. After an initial assessment, the participants will be randomly assigned to two groups. The intervention group will participate in a progressive multicomponent exercise regimen, including step aerobics and resistance training alternating every 2 weeks, for 50 min three times a week for 8 months. The reference group will be conducting home exercise program representing standard rehabilitative management for KOA patients. The primary outcome measures of this trial are the 8-month changes in the biochemical composition of the knee articular cartilage measured by the T1r and T2 relaxation times from quantitative magnetic resonance imaging and subchondral bone sclerosis, density and structure as measured via cone beam computed tomography. Measurements will be performed at baseline, after the 8-month intervention period, and at 12 months of maintenance. Discussion: This RCT investigates the effectiveness of a multicomponent exercise regimen on the subchondral bone and cartilage of the knee joint and the potential interaction between these tissues. The information gained will improve our understanding of the effects of exercise on subchondral bone and the biochemical properties of articular cartilage and improve the prescription of multicomponent exercise regimens in the management of mild KOA. Trial registration: ClinicalTrials.gov NCT06173193. Retrospectively registered before completion of the recruitment on 31 October 2023, https://www.clinicaltrials.gov/study/NCT06173193.


  • Open Access

    Correction: Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts

    by Heidelinde Sammallahti, Sama Rezasoltani, Satu Pekkala, Arto Kokkola, Hamid Asadzadeh Agdaei, Mehdi Azizmohammad Looha, Reza Ghanbari, Farhad Zamani, Amir Sadeghi, Virinder Kaur Sarhadi, et al.


  • Open Access

    Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts

    by Heidelinde Sammallahti, Sama Rezasoltani, Satu Pekkala, Arto Kokkola, Hamid Asadzadeh Agdaei, Mehdi Azizmohhammad Looha, Reza Ghanbari, Farhad Zamani, Amir Sadeghi, Virinder Kaur Sarhadi, et al.

    Background: Pancreatic cancer (PC) presents a significant challenge in oncology because of its late-stage diagnosis and limited treatment options. The inadequacy of current screening methods has prompted investigations into stool-based assays and microbial classifiers as potential early detection markers. The gut microbiota composition of PC patients may be influenced by population differences, thereby impacting the accuracy of disease prediction. However, comprehensive profiling of the PC gut microbiota and analysis of these cofactors remain limited. Therefore, we analyzed the stool microbiota of 33 Finnish and 50 Iranian PC patients along with 35 Finnish and 34 Iranian healthy controls using 16S rRNA gene sequencing. We assessed similarities and differences of PC gut microbiota in both populations while considering sociocultural impacts and generated a statistical model for disease prediction based on microbial classifiers. Our aim was to expand the current understanding of the PC gut microbiota, discuss the impact of population differences, and contribute to the development of early PC diagnosis through microbial biomarkers. Results: Compared with healthy controls, PC patients presented reduced microbial diversity, with discernible microbial profiles influenced by factors such as ethnicity, demographics, and lifestyle. PC was marked by significantly higher abundances of facultative pathogens including Enterobacteriaceae, Enterococcaceae, and Fusobacteriaceae, and significantly lower abundances of beneficial bacteria. In particular, bacteria belonging to the Clostridia class, such as butyrate-producing Lachnospiraceae, Butyricicoccaceae, and Ruminococcaceae, were depleted. A microbial classifier for the prediction of pancreatic ductal adenocarcinoma (PDAC) was developed in the Iranian cohort and evaluated in the Finnish cohort, where it yielded a respectable AUC of 0.88 (95% CI 0.78, 0.97). Conclusions: This study highlights the potential of gut microbes as biomarkers for noninvasive PC screening and the development of targeted therapies, emphasizing the need for further research to validate these findings in diverse populations. A comprehensive understanding of the role of the gut microbiome in PC could significantly enhance early detection efforts and improve patient outcomes.


  • Open Access

    Effects of high impact exercise on systemic cytokines in women with mild knee osteoarthritis: A 12-month RCT

    by Ville-Markus Konola, Juhani Multanen, Johanna K. Ihalainen, Jukka E. Hintikka, Timo Jämsä, Hannu Kautiainen, Miika T. Nieminen, Satu Pekkala, Maarit Valtonen, Ari Heinonen

  • Open Access

    Unveiling the impact of competition weight loss on gut microbiota: alterations in diversity, composition, and predicted metabolic functions

    by Anastasiia Driuchina, Ville Isola, Juha J Hulmi, Vera M Salmi, Jukka Hintikka, Juha P Ahtiainen, Satu Pekkala

    Competitive sports and sports nutrition, popular among amateur athletes aiming for a lean physique, have limited research on gut microbiota. We conducted a 46-week study to analyze the consequences of fat loss and diet restrictions in 23 fitness athletes who prepared for a physique competition. Body composition, dietary intakes, serum cytokines and chemokines, and fecal samples were analyzed. Fat loss through caloric restriction and aerobic exercise led to an increased phylogenetic diversity of gut microbiota and changes in the composition of gut microbiota, with Faecalibacterium, Lachnospiraceae, Bacteroides, and Intestinimonas showing altered abundances. Fat loss also changed the predicted microbial functions responsible for the metabolism of carbohydrates and amino acids. Consumption of energy, carbohydrates, fiber, vitamins and minerals, and various fatty acids decreased during the preparation for the competition, which was partly associated with changes in gut microbiota. Several cytokine levels decreased (IL1a, IL1b, IL10, and TFNα), and certain chemokine levels increased (GROa and RANTES). During the 23-week regain period after the competition, gut microbiota showed signs of recovery, with increased diversity compared to pre- and post-competition measurements. Most taxonomic changes returned to their baseline levels after the regain period. The study highlights the dynamic nature of gut microbiota and its response to fat loss and regain in non-obese fitness/physique competitors and provides novel insights into how competitive sports and sports nutrition can influence the gut ecosystem.


  • Open Access

    Prebiotic xylo-oligosaccharides for alleviation of hepatic steatosis: Results from a four-month dietary intervention and determinants of response

    by Jukka E Hintikka, Perttu Permi, Marko Lehtonen, Sanna Lensu, Anastasiia Driuchina, Mika Jormanainen, Jari Laukkanen, Nitin Bayal, Pande P. Erawijantari, Thomas M. O'Connell, et al.

    A common complexity from increasing rates of overweight is metabolic dysfunction associated steatotic liver disease (MASLD) which can develop into more severe conditions such as fibrosis or hepatocellular carcinoma. The gut and its microbial flora interact with the liver through the gut-liver axis and supporting healthy composition and metabolism of the microbiota can benefit metabolic health. We have previously shown in animals that a xylo-oligosaccharide (XOS) prebiotic can drive beneficial gut flora and ameliorate hepatic steatosis- our current objective is to validate these results in humans. Forty-two adults (mean age 53.7, mean BMI 33.5) ingested a prebiotic dose of XOS daily for four months. Liver fat was quantified with MRI and body composition was measured. Standard clinical measurements and untargeted metabolomes were analyzed from serum. Microbiota composition, metagenome and metabolites were analyzed from fecal samples. A subgroup analysis was conducted between non-steatotic individuals, non-responders, and responders. The XOS supplementation caused decreases in detrimental amino acid degradation products (AADPs) isovalerate, isobutyrate, and phenylacetate in the gut while serum metabolome remained stable. A decrease in liver fat during the prebiotic was accompanied by a decrease in visceral fat. In a prediction analysis, this response was driven by higher initial ratio of Bacteroides to Faecalibacterium , higher fecal AADPs, and higher serum amino acids. Non-responders had metabolomic signatures of advanced steatosis, possibly impeding effects from XOS. In overweight individuals with early hepatic steatosis, XOS may correct fermentation imbalances in the gut and decrease production of harmful metabolites, which may benefit hepatic health. IMPORTANCE: Pre- and probiotics are emerging, yet unknown, avenues of treatment for metabolism-associated steatotic liver disease. In overweight humans, a xylo-oligosaccharide (XOS) prebiotic induced shifts in gut bacteria and their metabolites. High proteolytic activity in the gut was predictive of hepatic response to XOS, which may serve the development of personalized treatment of fatty liver.

  • Open Access

    Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease

    by Satu Pekkala

    The frequency of non-alcoholic fatty liver disease (NAFLD) has intensified, creating diagnostic challenges and increasing the need for reliable non-invasive diagnostic tools. Due to the importance of the gut–liver axis in the progression of NAFLD, studies attempt to reveal microbial signatures in NAFLD, evaluate them as diagnostic biomarkers, and to predict disease progression. The gut microbiome affects human physiology by processing the ingested food into bioactive metabolites. These molecules can penetrate the portal vein and the liver to promote or prevent hepatic fat accumulation. Here, the findings of human fecal metagenomic and metabolomic studies relating to NAFLD are reviewed. The studies present mostly distinct, and even contradictory, findings regarding microbial metabolites and functional genes in NAFLD. The most abundantly reproducing microbial biomarkers include increased lipopolysaccharides and peptidoglycan biosynthesis, enhanced degradation of lysine, increased levels of branched chain amino acids, as well as altered lipid and carbohydrate metabolism. Among other causes, the discrepancies between the studies may be related to the obesity status of the patients and the severity of NAFLD. In none of the studies, except for one, was diet considered, although it is an important factor driving gut microbiota metabolism. Future studies should consider diet in these analyses.


  • Open Access

    Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease

    by Satu Pekkala

    The frequency of non-alcoholic fatty liver disease (NAFLD) has exacerbated setting diagnostic challenges, which increases the need for reliable non-invasive diagnostic tools. Due to the importance of gut-liver axis in the progression of NAFLD, studies try to reveal microbial signatures in NAFLD, evaluate them as diagnostic biomarkers and to predict the disease progression. The gut microbiome affects human physiology by processing the ingested food to bioactive metabolites. These molecules can penetrate the portal vein and the liver to promote or prevent hepatic fat accumulation. Here findings of human fecal metagenomic and metabolomic studies in relation to NAFLD are reviewed. The studies present mostly distinct and even contradictory findings on microbial metabolites and functional genes in NAFLD. The most reproducing microbial biomarkers are increased lipopolysaccharides and peptidoglycan biosynthesis, enhanced degradation of lysine, increased levels of branched chain amino acids as well as altered lipid and carbohydrate metabolism. Among other causes, the discrepancies between the studies may be related to the obesity status of the patients and severity of NAFLD. In none of the studies except one, diet was considered, though it is an important factor driving the gut microbiota metabolism. The future studies should consider diet in the analyses.